Emmanuel S Antonarakis1, Changxue Lu2, Brandon Luber3, Chao Liang2, Hao Wang3, Yan Chen2, John L Silberstein2, Danilo Piana2, Zhao Lai4, Yidong Chen5, William B Isaacs6, Jun Luo7. 1. Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA; Department of Urology, Johns Hopkins University School of Medicine, Baltimore, MD, USA. Electronic address: eantona1@jhmi.edu. 2. Department of Urology, Johns Hopkins University School of Medicine, Baltimore, MD, USA. 3. Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA. 4. Greehey Children's Cancer Research Institute, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA. 5. Greehey Children's Cancer Research Institute, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA; Department of Epidemiology and Biostatistics, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA. 6. Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA; Department of Urology, Johns Hopkins University School of Medicine, Baltimore, MD, USA. 7. Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA; Department of Urology, Johns Hopkins University School of Medicine, Baltimore, MD, USA. Electronic address: jluo1@jhmi.edu.
Abstract
BACKGROUND: Inherited DNA-repair gene mutations are more prevalent in men with advanced prostate cancer than previously thought, but their clinical implications are not fully understood. OBJECTIVE: To investigate the clinical significance of germline DNA-repair gene alterations in men with metastatic castration-resistant prostate cancer (mCRPC) receiving next-generation hormonal therapy (NHT), with a particular emphasis on BRCA/ATM mutations. DESIGN, SETTING, AND PARTICIPANTS: We interrogated 50 genes for pathogenic or likely pathogenic germline mutations using leukocyte DNA from 172 mCRPC patients beginning treatment with first-line NHT with abiraterone or enzalutamide. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: We assessed the impact of germline DNA-repair gene mutation status on ≥50% and ≥90% PSA responses, PSA progression-free survival (PSA-PFS), clinical/radiologic progression-free survival (PFS), and overall survival (OS). Survival outcomes were adjusted using propensity score-weighted multivariable Cox regression analyses. RESULTS AND LIMITATIONS: Among 172 mCRPC patients included, germline mutations (in any DNA-repair gene) were found in 12% (22/172) of men, and germline BRCA/ATM mutations specifically in 5% (9/172) of men. In unadjusted analyses, outcomes to first-line NHT were better in men with germline BRCA/ATM mutations (vs no mutations) with respect to PSA-PFS (hazard ratio [HR] 0.47; p=0.061), PFS (HR 0.50; p=0.090), and OS (HR 0.28; p=0.059). In propensity score-weighted multivariable analyses, outcomes were superior in men with germline BRCA/ATM mutations with respect to PSA-PFS (HR 0.48, 95% confidence interval [CI] 0.25-0.92; p=0.027), PFS (HR 0.52, 95% CI 0.28-0.98; p=0.044), and OS (HR 0.34, 95% CI 0.12-0.99; p=0.048), but not in men with non-BRCA/ATM germline mutations (all p>0.10). These results require prospective validation, and our conclusions are limited by the small number of patients (n=9) with BRCA/ATM mutations. CONCLUSIONS: Outcomes to first-line NHT appear better in mCRPC patients harboring germline BRCA/ATM mutations (vs no mutations), but not for patients with other non-BRCA/ATM germline mutations. PATIENT SUMMARY: Patients with metastatic castration-resistant prostate cancer and harboring germline mutations in BRCA1/2 and ATM benefit from treatment with abiraterone and enzalutamide.
BACKGROUND: Inherited DNA-repair gene mutations are more prevalent in men with advanced prostate cancer than previously thought, but their clinical implications are not fully understood. OBJECTIVE: To investigate the clinical significance of germline DNA-repair gene alterations in men with metastatic castration-resistant prostate cancer (mCRPC) receiving next-generation hormonal therapy (NHT), with a particular emphasis on BRCA/ATM mutations. DESIGN, SETTING, AND PARTICIPANTS: We interrogated 50 genes for pathogenic or likely pathogenic germline mutations using leukocyte DNA from 172 mCRPC patients beginning treatment with first-line NHT with abiraterone or enzalutamide. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: We assessed the impact of germline DNA-repair gene mutation status on ≥50% and ≥90% PSA responses, PSA progression-free survival (PSA-PFS), clinical/radiologic progression-free survival (PFS), and overall survival (OS). Survival outcomes were adjusted using propensity score-weighted multivariable Cox regression analyses. RESULTS AND LIMITATIONS: Among 172 mCRPC patients included, germline mutations (in any DNA-repair gene) were found in 12% (22/172) of men, and germline BRCA/ATM mutations specifically in 5% (9/172) of men. In unadjusted analyses, outcomes to first-line NHT were better in men with germline BRCA/ATM mutations (vs no mutations) with respect to PSA-PFS (hazard ratio [HR] 0.47; p=0.061), PFS (HR 0.50; p=0.090), and OS (HR 0.28; p=0.059). In propensity score-weighted multivariable analyses, outcomes were superior in men with germline BRCA/ATM mutations with respect to PSA-PFS (HR 0.48, 95% confidence interval [CI] 0.25-0.92; p=0.027), PFS (HR 0.52, 95% CI 0.28-0.98; p=0.044), and OS (HR 0.34, 95% CI 0.12-0.99; p=0.048), but not in men with non-BRCA/ATM germline mutations (all p>0.10). These results require prospective validation, and our conclusions are limited by the small number of patients (n=9) with BRCA/ATM mutations. CONCLUSIONS: Outcomes to first-line NHT appear better in mCRPC patients harboring germline BRCA/ATM mutations (vs no mutations), but not for patients with other non-BRCA/ATM germline mutations. PATIENT SUMMARY:Patients with metastatic castration-resistant prostate cancer and harboring germline mutations in BRCA1/2 and ATM benefit from treatment with abiraterone and enzalutamide.
Authors: Rong Na; S Lilly Zheng; Misop Han; Hongjie Yu; Deke Jiang; Sameep Shah; Charles M Ewing; Liti Zhang; Kristian Novakovic; Jacqueline Petkewicz; Kamalakar Gulukota; Donald L Helseth; Margo Quinn; Elizabeth Humphries; Kathleen E Wiley; Sarah D Isaacs; Yishuo Wu; Xu Liu; Ning Zhang; Chi-Hsiung Wang; Janardan Khandekar; Peter J Hulick; Daniel H Shevrin; Kathleen A Cooney; Zhoujun Shen; Alan W Partin; H Ballentine Carter; Michael A Carducci; Mario A Eisenberger; Sam R Denmeade; Michael McGuire; Patrick C Walsh; Brian T Helfand; Charles B Brendler; Qiang Ding; Jianfeng Xu; William B Isaacs Journal: Eur Urol Date: 2016-12-15 Impact factor: 20.096
Authors: Dan Robinson; Eliezer M Van Allen; Yi-Mi Wu; Nikolaus Schultz; Robert J Lonigro; Juan-Miguel Mosquera; Bruce Montgomery; Mary-Ellen Taplin; Colin C Pritchard; Gerhardt Attard; Himisha Beltran; Wassim Abida; Robert K Bradley; Jake Vinson; Xuhong Cao; Pankaj Vats; Lakshmi P Kunju; Maha Hussain; Felix Y Feng; Scott A Tomlins; Kathleen A Cooney; David C Smith; Christine Brennan; Javed Siddiqui; Rohit Mehra; Yu Chen; Dana E Rathkopf; Michael J Morris; Stephen B Solomon; Jeremy C Durack; Victor E Reuter; Anuradha Gopalan; Jianjiong Gao; Massimo Loda; Rosina T Lis; Michaela Bowden; Stephen P Balk; Glenn Gaviola; Carrie Sougnez; Manaswi Gupta; Evan Y Yu; Elahe A Mostaghel; Heather H Cheng; Hyojeong Mulcahy; Lawrence D True; Stephen R Plymate; Heidi Dvinge; Roberta Ferraldeschi; Penny Flohr; Susana Miranda; Zafeiris Zafeiriou; Nina Tunariu; Joaquin Mateo; Raquel Perez-Lopez; Francesca Demichelis; Brian D Robinson; Andrea Sboner; Marc Schiffman; David M Nanus; Scott T Tagawa; Alexandros Sigaras; Kenneth W Eng; Olivier Elemento; Andrea Sboner; Elisabeth I Heath; Howard I Scher; Kenneth J Pienta; Philip Kantoff; Johann S de Bono; Mark A Rubin; Peter S Nelson; Levi A Garraway; Charles L Sawyers; Arul M Chinnaiyan Journal: Cell Date: 2015-07-16 Impact factor: 41.582
Authors: Mark M Pomerantz; Sandor Spisák; Li Jia; Angel M Cronin; Istvan Csabai; Elisa Ledet; A Oliver Sartor; Irene Rainville; Edward P O'Connor; Zachary T Herbert; Zoltan Szállási; William K Oh; Philip W Kantoff; Judy E Garber; Deborah Schrag; Adam S Kibel; Matthew L Freedman Journal: Cancer Date: 2017-06-13 Impact factor: 6.860
Authors: Matti Annala; Werner J Struss; Evan W Warner; Kevin Beja; Gillian Vandekerkhove; Amanda Wong; Daniel Khalaf; Irma-Liisa Seppälä; Alan So; Gregory Lo; Rahul Aggarwal; Eric J Small; Matti Nykter; Martin E Gleave; Kim N Chi; Alexander W Wyatt Journal: Eur Urol Date: 2017-03-01 Impact factor: 20.096
Authors: E A Eisenhauer; P Therasse; J Bogaerts; L H Schwartz; D Sargent; R Ford; J Dancey; S Arbuck; S Gwyther; M Mooney; L Rubinstein; L Shankar; L Dodd; R Kaplan; D Lacombe; J Verweij Journal: Eur J Cancer Date: 2009-01 Impact factor: 9.162
Authors: Howard I Scher; Susan Halabi; Ian Tannock; Michael Morris; Cora N Sternberg; Michael A Carducci; Mario A Eisenberger; Celestia Higano; Glenn J Bubley; Robert Dreicer; Daniel Petrylak; Philip Kantoff; Ethan Basch; William Kevin Kelly; William D Figg; Eric J Small; Tomasz M Beer; George Wilding; Alison Martin; Maha Hussain Journal: J Clin Oncol Date: 2008-03-01 Impact factor: 44.544
Authors: Elena Castro; Chee Goh; Daniel Leongamornlert; Ed Saunders; Malgorzata Tymrakiewicz; Tokhir Dadaev; Koveela Govindasami; Michelle Guy; Steve Ellis; Debra Frost; Elizabeth Bancroft; Trevor Cole; Marc Tischkowitz; M John Kennedy; Jacqueline Eason; Carole Brewer; D Gareth Evans; Rosemarie Davidson; Diana Eccles; Mary E Porteous; Fiona Douglas; Julian Adlard; Alan Donaldson; Antonis C Antoniou; Zsofia Kote-Jarai; Douglas F Easton; David Olmos; Rosalind Eeles Journal: Eur Urol Date: 2014-11-06 Impact factor: 20.096
Authors: William R Polkinghorn; Joel S Parker; Man X Lee; Elizabeth M Kass; Daniel E Spratt; Phillip J Iaquinta; Vivek K Arora; Wei-Feng Yen; Ling Cai; Deyou Zheng; Brett S Carver; Yu Chen; Philip A Watson; Neel P Shah; Sho Fujisawa; Alexander G Goglia; Anuradha Gopalan; Haley Hieronymus; John Wongvipat; Peter T Scardino; Michael J Zelefsky; Maria Jasin; Jayanta Chaudhuri; Simon N Powell; Charles L Sawyers Journal: Cancer Discov Date: 2013-09-11 Impact factor: 39.397
Authors: Colin C Pritchard; Joaquin Mateo; Michael F Walsh; Navonil De Sarkar; Wassim Abida; Himisha Beltran; Andrea Garofalo; Roman Gulati; Suzanne Carreira; Rosalind Eeles; Olivier Elemento; Mark A Rubin; Dan Robinson; Robert Lonigro; Maha Hussain; Arul Chinnaiyan; Jake Vinson; Julie Filipenko; Levi Garraway; Mary-Ellen Taplin; Saud AlDubayan; G Celine Han; Mallory Beightol; Colm Morrissey; Belinda Nghiem; Heather H Cheng; Bruce Montgomery; Tom Walsh; Silvia Casadei; Michael Berger; Liying Zhang; Ahmet Zehir; Joseph Vijai; Howard I Scher; Charles Sawyers; Nikolaus Schultz; Philip W Kantoff; David Solit; Mark Robson; Eliezer M Van Allen; Kenneth Offit; Johann de Bono; Peter S Nelson Journal: N Engl J Med Date: 2016-07-06 Impact factor: 91.245
Authors: Wafik S El-Deiry; Richard M Goldberg; Heinz-Josef Lenz; Anthony F Shields; Geoffrey T Gibney; Antoinette R Tan; Jubilee Brown; Burton Eisenberg; Elisabeth I Heath; Surasak Phuphanich; Edward Kim; Andrew J Brenner; John L Marshall Journal: CA Cancer J Clin Date: 2019-05-22 Impact factor: 508.702
Authors: Tamara L Lotan; Harsimar B Kaur; Abdullah M Alharbi; Colin C Pritchard; Jonathan I Epstein Journal: Histopathology Date: 2019-04-01 Impact factor: 5.087
Authors: Julie L Boyle; Andrew W Hahn; Ashley L Kapron; Wendy Kohlmann; Samantha E Greenberg; Timothy J Parnell; Craig C Teerlink; Benjamin L Maughan; Bing-Jian Feng; Lisa Cannon-Albright; Neeraj Agarwal; Kathleen A Cooney Journal: JCO Precis Oncol Date: 2020-03-04
Authors: Siddhartha Yadav; Steven N Hart; Chunling Hu; David Hillman; Kun Y Lee; Rohan Gnanaolivu; Jie Na; Eric C Polley; Fergus J Couch; Manish Kohli Journal: JCO Precis Oncol Date: 2019-09-17